InflaRx N.V.

IFRX

NL0012661870

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:59:22 18/06/2025 BST			5-day change	1st Jan Change
0.8120 ^USD	+5.47%		-2.51%	-67.13%

05-29	Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating	MT
05-29	Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13	MT

Sector Update: Health Care Stocks Advance Monday Afternoon

Published on 24/06/2024 at 18:58, updated on 24/06/2024 at 18:59

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about InflaRx N.V.

Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating	05-29	MT
Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13	05-29	MT
Sector Update: Health Care Stocks Softer Late Afternoon	05-28	MT
Top Midday Decliners	05-28	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	05-28	MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday.	05-28	MT
InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell	05-28	MT
Inflarx N.V. Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum	05-28	CI
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025.	05-15	CI
Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025.	05-15	CI
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025.	05-15	CI
InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-07	CI
Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target	04-29	MT
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2024	03-20	CI
Sector Update: Health Care Stocks Flat to Higher Premarket Friday	02-14	MT
InflaRx Slumps Premarket After Pricing $30 Million Offering of Ordinary Shares, Pre-Funded Warrants	02-14	MT
Inflarx Announces Public Offering Of Ordinary Shares And Pre-Funded Warrants	02-13	RE
Sector Update: Health Care Stocks Advance Late Afternoon	01-15	MT
InflaRx Gets Marketing Approval for COVID-19 Therapy in Europe	01-15	MT
InflaRx N.V. Receives European Commission Approval for GOHIBIC®? (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome	01-15	CI
Inflarx N.V. Announces First Patient Dosed in Phase 2A Study for Oral C5aR Inhibitor INF904	12-20	CI
InflaRx Says Severe Covid Drug Gets EU Panel's Positive Opinion; Shares Rise Pre-Bell	11-15	MT
InflaRx N.V. Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome	11-15	CI
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-08	CI
Earnings Flash (IFRX) INFLARX N.V. Posts Q2 Revenue EUR6,357	08/08/24	MT

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Employees

Sector

Biotechnology & Medical Research

Calendar

06-25 - Oppenheimer Innovators Summit

More about the company